Edition:
Deutschland

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

283.00USD
28 Oct 2020
Change (% chg)

$-7.51 (-2.59%)
Prev Close
$290.51
Open
$286.87
Day's High
$290.30
Day's Low
$279.84
Volume
147,891
Avg. Vol
132,179
52-wk High
$318.73
52-wk Low
$119.46

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Buy/Sell

Sell Hold Buy
2.33 Mean rating from 9 analysts

Overall

Beta: 0.21
Market Cap(Mil.): $7,712.59
Shares Outstanding(Mil.): 44.10
Dividend: --
Yield (%): --
Photo

Big Tech drives S&P 500 to record high in coronavirus rally

The S&P 500 hit a record high on Tuesday, thanks largely to months of outperformance from Amazon and other heavyweight technology companies viewed by investors as likely to emerge from the coronavirus crisis stronger than smaller rivals.

Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients

Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures.

Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients

Aug 4 Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures.

BRIEF-ABIOMED Says 2020 Total Compensation For CEO Michael Minogue $16.6 Mln Versus $19.2 Mln In 2019

* ABIOMED INC - 2020 TOTAL COMPENSATION FOR CEO MICHAEL MINOGUE $16.6 MILLION VERSUS $19.2 MILLION IN 2019

BRIEF-Abiomed Appoints Charles Simonton As New Chief Medical Officer

* ABIOMED APPOINTS NEW CHIEF MEDICAL OFFICER CHARLES SIMONTON, M.D. Source text for Eikon: Further company coverage:

BRIEF-FDA Approves Abiomed’s First-In-Human Trial Of Impella ECP

* FDA APPROVES ABIOMED’S FIRST-IN-HUMAN TRIAL OF IMPELLA ECP, WORLD’S SMALLEST HEART PUMP Source text for Eikon: Further company coverage:

FDA approves emergency use of Abiomed heart pump for COVID-19 patients

June 1 Abiomed Inc said on Monday the U.S. Food and Drug Administration has granted emergency use authorization for its temporary invasive heart pump to help patients suffering from COVID-19 related right heart failure.

BRIEF-FDA Issues EUA For Impella RP For Covid-19 Patients With Right Heart Failure

* FDA ISSUES EMERGENCY USE AUTHORIZATION FOR IMPELLA RP AS THERAPY FOR COVID-19 PATIENTS WITH RIGHT HEART FAILURE Source text for Eikon: Further company coverage:

U.S. RESEARCH ROUNDUP- Comcast, Mirati Therapeutics, Oceanfirst Financial

May 1 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comcast, Mirati Therapeutics and Oceanfirst Financial, on Friday. HIGHLIGHTS * Comcast Corp : Keybanc cuts to sector weight from overweight * Mirati Therapeutics Inc : JP Morgan raises to overweight from neutral * Oceanfirst Financial Corp : Stephens raises to overweight from equal-weight * Wolveri

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.21%
Rohstoffe -0.11%
Industrie -0.13%
Konjunktur abhängige Waren & Dienstleistungen +0.04%
Konjunktur unabhängige Waren & Dienstleistungen -0.03%
Finanzindustrie -0.00%
Pharma +0.01%
Technologie +0.00%